newsfilter
← Latest News
Business Wire·

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290 million Hosts